Ventilatory and cardiovascular actions of centrally and peripherally administered trout pituitary adenylate cyclase-activating polypeptide (PACAP) and vasoactive intestinal peptide (VIP) in the unanaesthetized trout.

In mammals, pituitary adenylate cyclase-activating polypeptide (PACAP) and vasoactive intestinal peptide (VIP) are involved in cardiovascular and respiratory regulation. Several studies have demonstrated the presence of PACAP, VIP and their receptors in various tissues of teleost fish, including the brain, but little is known about their respiratory and cardiovascular effects. The present study was undertaken to compare the central and peripheral actions of graded doses (25-100 pmol) of trout PACAP and trout VIP on ventilatory and cardiovascular variables in the unanaesthetized rainbow trout. Compared with vehicle, only intracerebroventricular injection of PACAP significantly (P<0.05) elevated the ventilation frequency and the ventilation amplitude, but both peptides significantly increased the total ventilation (total ventilation). However, the maximum hyperventilatory effect of PACAP was approximately 2.5-fold higher than the effect of VIP at the 100 pmol dose (PACAP, (total ventilation)=+5407+/-921 arbitrary units, a.u.; VIP, (total ventilation)=+2056+/-874 a.u.; means +/- s.e.m.). When injected centrally, only PACAP produced a significant increase in mean dorsal aortic blood pressure (P(DA)) (100 pmol: +21%) but neither peptide affected heart rate (f(H)). Intra-arterial injections of either PACAP or VIP were without effect on the ventilatory variables. PACAP was without significant action on P(DA) and f(H) while VIP significantly elevated P(DA) (100 pmol: +36%) without changing f(H). In conclusion, the selective central hyperventilatory actions of exogenously administered trout PACAP, and to a lesser extent VIP, suggest that the endogenous peptides may be implicated in important neuroregulatory functions related to the central control of ventilation in trout.

Time-course effects of centrally administered native urotensin-II on motor and cardioventilatory activity in trout.

Although in most vertebrate species urotensin-II (UII) is synthesized in neurons of the central nervous system, little is known regarding the physiological actions of UII in the brain. We have investigated the effects of intracerebroventricular (ICV) administration of synthetic trout UII (1, 5, and 50 pmol) on total motor activity (ACT), ventilatory frequency (VF), ventilatory amplitude (VA), and heart rate (HR) in the unanesthetized trout. ICV injection of UII increased ACT in a dose-dependent manner, and the maximal effect was observed at a dose of 5 pmol. At doses of 1 and 5 pmol, UII did not affect VF, VA, or HR. At the highest dose tested (50 pmol), UII not only increased ACT, but also significantly activated VF, VA, and HR. In contrast, ICV injection of synthetic trout angiotensin-II (5 pmol) did not produce any effect on ACT, VF, or VA, but sharply increased HR. These data provide the first evidence that UII can act centrally to induce motor activity in a nonmammalian vertebrate species.

Intracerebroventricular injection of arginine vasotocin induces elevation of blood pressure in anesthetized trout.

The present investigation assessed the ability of the neurohypophysial nonapeptide arginine vasotocin (AVT) to centrally regulate the cardiovascular activity in fish. Intracerebroventricular (ICV) injection of AVT (0.4 to 50 ng/kg b.wt.) in anesthetized trout resulted in a dose-related increase in blood pressure (BP) without any consistent changes in heart rate. For doses of AVT ranging from 2 to 50 ng/kg b.wt., BP remained elevated during at least 25 min after ICV injection. Systemic (intraarterial) administration of the same doses of AVT appeared to be less efficient than ICV injection, except for the highest dose (50 ng/kg) which evoked a similar rise in BP as that observed after ICV administration. In contrast to AVT, a high concentration of neuropeptide Y (10 micrograms/kg b.wt., ICV) caused only a slight increase of BP. The results suggest that AVT acts centrally to regulate BP in fish. These data, together with the widespread distribution of AVT-immunoreactive fibers and AVT binding sites in the brain, support the notion that, in fish, AVT may play neuromodulator and/or neurotransmitter functions.

Isolation and cardiovascular activity of a second bradykinin-related peptide ([Arg0, Trp5, Leu8]bradykinin) from trout.

Previous work has shown that incubation of heat-denatured plasma from the rainbow trout Oncorhynchus mykiss with porcine pancreatic kallikrein generates [Lys0, Trp5, Leu8]bradykinin (trout [Lys0]BK). We have now isolated a second BK-related peptide from kallikrein-treated trout plasma with the primary structure: Arg-Arg-Pro-Gly-Trp-Ser-Pro-Leu-Arg (trout [Arg0]BK). Bolus injections of both trout [Arg0]BK and [Lys0]BK (> 100 pmol/kg) into the dorsal aorta of conscious trout produced multiphasic effects on arterial blood pressure. An initial pressor response of short duration (1-2 min) was followed by a fall in pressure (to below basal values in 11 out of 15 animals) and then by a sustained rise in pressure lasting up to 60 min. The maximum rise in pressure produced by trout [Arg0]BK (10 nmol/kg) was approximately one-fourth of the maximum rise produced by angiotensin II in the same animals. Intracerebroventricular injections of trout [Arg0]BK (500 pmol) into conscious trout had no effect on arterial blood pressure or heart rate. Trout [Arg0]BK did not affect the tension of vascular rings from trout efferent branchial and caeliacomesenteric arteries and anterior cardinal vein. Trout des [Arg9]BK had no effect on cardiovascular parameters, either in vivo or in vitro, indicating that the C-terminal arginine residue of the peptide is important in interaction with the trout kinin receptor(s).

Effects of central and peripheral administration of arginine vasotocin and related neuropeptides on blood pressure and heart rate in the conscious trout.

The cardiovascular activity of neurohypophyseal peptides has been investigated in conscious trout bearing an intracerebroventricular guide cannula and a permanent intraarterial catheter. Changes in diastolic pressure, systolic pressure and heart rate were monitored during the 25-min period following intracerebroventricular or intraarterial administration of arginine vasotocin and related neuropeptides, including arginine vasopressin, oxytocin, hydrin-2, mesotocin, isotocin and conopressin-S. Intracerebroventricular injection of increasing doses of arginine vasotocin (0.62-5 pmol) induced a dose-dependent increase of diastolic and systolic pressures. The onset of the response occurred within 3-5 min after intracerebroventricular administration of arginine vasotocin and the maximal increase was reached at 10-15 min. Central administration of vasopressin and oxytocin induced a significant rise in diastolic and systolic pressures at a dose of 5 pmol while hydrin-2 only caused a significant elevation of blood pressure at a dose of 50 pmol. Central administration of mesotocin, isotocin and conopressin-S (5-500 pmol each) had no significant effect on blood pressure. No changes in heart rate occurred after intracerebroventricular injection of any of the seven neuropeptides tested. Intraarterial injection of arginine vasotocin (50 pmol) induced a significant rise in blood pressure and bradycardia. Peripheral injection of the other neuropeptides did not cause any modification of the cardiovascular activity, whatever the doses administered (5-500 pmol). The V1A receptor antagonist [d(CH2)5, Tyr(OMe)2]arginine vasopressin had no intrinsic effect on blood pressure and heart rate when injected centrally (50 pmol) or in the peripheral circulation (200 pmol). At the same doses, [d(CH2)5, Tyr(OMe)2]arginine vasopressin reduced by 50 and 66%, respectively, the increase in blood pressure evoked by intracerebroventricular (5 pmol) or intraarterial (50 pmol) injections of arginine vasotocin.(ABSTRACT TRUNCATED AT 250 WORDS)

Intracerebroventricular administration of angiotensin II increases heart rate in the conscious trout.

The central effect of angiotensin II on cardiovascular activity has been investigated in conscious trout bearing an intracerebroventricular (i.c.v.) cannula and an intra-arterial catheter. I.c.v. injection of the angiotensin II agonist [Asn1,Val5]AII (6.2-50 pmol) induced a dose-dependent increase in heart rate and arterial blood pressure. Central administration of the angiotensin II antagonist DuP 753 (5 nmol) 30 min before i.c.v. injection of [Asn1,Val5]AII totally prevented the tachycardia and reduced the hypertension induced by the angiotensin II agonist. Intra-arterial injection of arginine-vasotocin (12.5 pmol) caused a bradycardia associated with a marked increase in arterial blood pressure. I.c.v. injection of [Asn1,Val5]AII totally blocked the bradycardia induced by arginine-vasotocin and this effect was prevented by central administration of DuP 753. In contrast, [Asn1,Val5]AII did not affect the increase in blood pressure induced by arginine vasotocin. Suppression of the vagal tone by atropine treatment totally blocked the central effect of [Asn1,Val5]AII. These results show that angiotensin II acts directly on the trout brain to increase blood pressure and heart rate. The effect of angiotensin II is mediated through a receptor related to the mammalian AT1 receptor type.

Role of dorsal vagal motor nucleus in angiotensin II-mediated tachycardia in the conscious trout Oncorhynchus mykiss.

Responses of heart rate (HR) and mean arterial blood pressure (MABP) were examined following microinjection of angiotensin II ([Asn1,Val5]AI) within the dorsal vagal motor nucleus (DVN) of the conscious trout's brainstem. AII (15-125 fmol) preferentially and significantly increased HR in a dose-dependent manner, but the rise in MABP was not dose-dependent and was only significant (P < 0.05) after injection of AII at a dose of 62.5 fmol. The cardiovascular action of AII was site-specific, since administrations of the peptide at a dose of 62.5 fmol, but outside the boundaries of the DVN, were devoid of any effect on HR or MABP. All the responses to DVN injections of AII were totally prevented by DVN injection of 1 nmol of losartan, a mammalian non-peptide AII subtype 1 (AT1) receptor antagonist. The ability of DVN injection of AII to induce a tachycardic response was negatively correlated to HR basal values. In conclusion, these results indicate that, at femtomolar doses, AII exerts a central neurocardioregulatory role, involving a localized receptor closely related to the mammalian AT1 receptor subtype within the DVN of the trout.

[Adrenoleukodystrophy in the child and adrenomyeloneuropathy. Study of 2 families]. / Adrénoleucodystrophie de l'enfant et adrénomyéloneuropathie. Etude de deux familles.

Ten subjects from 2 families with adrenoleukodystrophy (ALD) and adrenomyeloneuropathy (AMN), hereditary X-linked diseases, were systematically explored. We performed endocrinological, biochemical assays and neurophysiological tests; the latter consisted of nerve conductions (CNV), Hoffmann's reflex and multimodal evoked potentials: visual (flash and pattern, VEP), brainstem auditory (BAEP) and somesthetic (SEP) using median nerve stimulation at the wrist. We only considered values above 2 SD. The purpose of our study was to determine the correlation between neurophysiological and endocrinological perturbations and the presence of pathological traits. Our results suggest that the correlation is high in diseased male patients, lower for the ALD carriers (BAEP, SEP and CNV were more frequently abnormal) and very low for the AMN carriers. Only the biochemical assays appeared to have any value for the characterization of female carriers of ALD and AMN.

[Long-term effects of treatment with SMS 201-995 on sleep apnea syndrome associated with acromegaly]. / Effets à long terme du traitement par SMS 201-995 sur un syndrome d'apnées du sommeil associé à une acromégalie.

A 60-year-old woman with acromegaly associated with sleep apnea was treated with the somatostatin analogue SMS 201-995 (Sandoz) for several months. Growth hormone levels were normalized and a rapid improvement in sleep apnea was controlled with polygraphic nocturnal monitoring. Hypophysectomy seems to have variable effects on sleep apnea in acromegaly. The origin of obstructive apnea in acromegaly is therefore unclear.

[Pituitary adenoma secreting somatotropic hormone. Gigantism and peripheral neuropathy. A case]. / Adénome hypophysaire sécrétant de l'hormone somatotrope. Gigantisme et neuropathie périphérique. Une observation.

Gigantism, an extremely rare condition, develops before puberty or in subjects in whom puberty is not yet completed. Hypersecretion of somatotropic hormone results in a tremendous surge in growth (our patient was 2.36 m tall). Among other clinical symptoms disabling peripheral neuropathy predominates and changes in nerve conduction velocity are not merely due to the increase in height. The increase in growth hormone concentrations combined with hypogonadotrophic hypogonadism with normal prolactinaemia is associated with peculiar cutaneous symptoms and with low levels of sex hormone-binding protein.

Central and peripheral cardiovascular effects of angiotensin III in trout.

The present study was undertaken to determine the central and peripheral actions of trout angiotensin III (ANG III) on heart rate (HR) and mean dorsal aortic blood pressure (P(DA)) in the unanaesthetized rainbow trout. Intracerebroventricular injection of ANG III (5-100 pmol) produced a significant and dose-dependent increase in HR without significant change in P(DA). In contrast, when injected peripherally ANG III (5-50 pmol) evoked a significant and dose-dependent increase in P(DA). The hypertensive responses were accompanied by a bradycardia that reached significance only for the highest dose of ANG III tested. In conclusion, our results have shown that ANG III has potent and contrasting cardiovascular actions depending on whether its site of action is the brain or the peripheral circulation. Endogenous ANG III may have important physiological functions in teleost fishes.

Patterns of spontaneous unit preoptic neurosecretory cell discharges in the rainbow trout, Salmo gairdneri.

Extracellular antidromic potentials recorded from the neurosecretory cell body were characterized by the following criteria: constant latency, the ability to follow a high frequency rate of stimulation and the collision test. The latency of the antidromic potentials ranged from 12 to 24 ms (17.46 +/- 3.10 SD) which gave a mean conduction velocity of 0.19 m/s, typical of unmyelinated nerve fibers. Two components could be clearly distinguished in the antidromic potential. A small "A" spike which showed constant latency and a large "B" spike with a variable latency and amplitude. A delay of 6.5 ms between the two spikes could occur and sometimes the "B" spike was blocked leaving only the "A" spike. Four patterns of spontaneous activity seem to emerge: Type I (26% of units, M +/- SD = 0.77 +/- 0.32 sp/s) corresponds to a slow and irregular pattern of activity; Type II (28% of units, M = 1.58 +/- 0.47 sp/s) is hard to classify and may be related to an irregular bursting pattern of activity; Type III (28% of units, M = 2.59 +/- 1.19 sp/s) corresponds to a continuous pattern of activity; Type IV (18% of units) represents a rhythmic pattern of activity with an active phase of about 3 min (M = 2.42 +/- 0.90 min), a silent phase of about 4 min (M = 3.89 +/- 3.02 min) and a maximal frequency of unit discharge in the range 2-18 sp/s. No statistical differences exist for the mean dorsal aortic pressure (DAP) between the four types of neurosecretory cell activity.

Spontaneous multiple unit activity from the preoptic nucleus and changes in blood pressure in the rainbow trout Salmo gairdneri under acute experimental conditions.

Multiple unit activity (MUA) from the preoptic nucleus (NPO) blood pressure and heart rate were recorded in 41 anaesthetized and curarized rainbow trout. Mayer waves were frequently observed in blood pressure recordings (83%). Rhythmic MUA from the NPO, recorded in 46% of the experimented trout, occurred preferentially during Mayer waves. The initiation of the period of MUA occurred during low pressure vasomotor tone and large vasomotor pulse pressure inhibited MUA. Sustained decrease in blood pressure induced proportional rise in MUA. These results suggest that cardiovascular inputs influence the electrical activity of neurosecretory cells within the NPO and so may modulate the neurohypophysial hormones secretion.

Evidence for biorhythmicity from the preoptic nucleus of the rainbow trout Salmo gairdnerii under freely swimming conditions--an electrophysiological study.

This study describes a technique which allows continuous recording of MUA (Multiple Unit Activity), from the NPO (Preoptic Nucleus), DAP (Dorsal Aortic blood Pressure) and ECG (Electrocardiogram) in freely swimming rainbow trout. From the 21 trout tested, six trout (29%) clearly showed rhythmic patterns of MUA during the five post-operative days (D2-D6). The mean length of rhythmic MUA was about 18 hr (range 6-33 hr) among the six trout during the recording days. Periodic MUA occurred approximately eight times/hr and lasted about 2 min. The maximal frequency of discharges was 20-30 spikes per sec. No change occurred in the mean level of blood pressure from the first operative day to the following post-operative days, where rhythmic MUA appeared or reappeared. These results demonstrate the existence of biorhythmicity within the NPO of freely swimming trout and suggest parallel oscillations in neurohormones secretion.

[Corticohypophysiotropic and corticotropic activity in adrenalectomized male and female rats after psychic stress]. / Activités corticohypophysiotrope et corticotrope chez le rat après une agression pyschique: effects du sexe et de la surrénalectomie.

We show modifications in the hypothalamic CRF activity and plasma ACTH concentration in adult rats of both sexes, which were five day sham-operated or adrenalectomized and killed either under basal conditions or after a 3 min period or psychological stress. 1. Under basal conditions, the inhibition of the basal release of ACTH is suppressed in 5 day adrenalectomized rats and a sex difference appears: plasma ACTH concentration is twice as great in females than in males. 2. After a 3 min period of psychological stress, the usual increase in hypothalamic CRF activity observed in sham-operated rats, which seems to be sex-related, does not appear in adrenalectomized male or female rats. However, in adrenalectomized rats, the maximal increase in plasma ACTH concentration occurred more rapidly, with a rate 10 times as great in males and 4 times as great in females, than in sham-operated rats. Differences between the sexes in the maximal increase in plasma ACTH concentration remains 1,6 times as great in females than in males. 3. Our results confirm that corticosteroids exert: (1) a tonic feedback inhibition of the basal release of ACTH, (2) a fast feedback inhibition of the stress induced release of ACTH; the promote an increase in the hypothalamic CRF content. Relative intensity of these two inhibitory mechanisms seems to be sex-related.

[Peripheral neuropathies during treatment with cisplatin: clinical and electrophysiologic study of 11 cases]. / Neuropathies périphériques au cours des traitements au cisplatine: étude clinique et électrophysiologique de 11 cas.

Eleven patients with bronchial epidermoid carcinoma and undergoing treatment with cis-D.D.P. (II) were kept under electrophysiological and clinical surveillance. No other neurotoxic medication was added. The total dose of cis-D.D.P. was 300 mg/m2 over a period of three months: namely, three courses of 100 mg/m2 distributed over 5 days. Following the pretreatment check-up, the patients were divided into two groups: those without any electrophysiological abnormality (group A), and those without clinical abnormality but with a delayed latency H of the Hoffmann Reflex (group B). Patients in group A showed a slowing down of the motor nerve conduction velocity of the Median and Peroneal Nerves after a course of 100 mg, without accompanying worsening of the conduction velocity after 300 mg/m2, and prolongation of the distal latency of the sensory Median Nerve after 300 mg/m2; in group B, no significant change of electrophysiological clinical features were noted. In the two groups a non-significant reduction in amplitude of evoked responses were noted. These findings are more consistent with an axonal injury than with functional myelin injury. The authors review the existing literature and discuss the physiopathologic mechanisms of cis-D.D.P. peripheral neuropathies.

Central and peripheral administration of endothelin-1 induces an increase in blood pressure in conscious trout.

The central and peripheral cardiovascular effects of endothelin (ET)-1 and ET-3 were investigated in conscious rainbow trout. Both intracerebroventricular and intra-arterial injections of ET-1 (6. 25-25 pmol) but not ET-3 (25 pmol) caused a dose-dependent increase in mean dorsal aortic blood pressure and a concomitant decrease in heart rate. The hypertensive effects induced by intra-arterial and intracerebroventricular injection of ET-1 were associated with a significant (P < 0.05) increase in systemic vascular resistance. Intracerebroventricular injection of ET-1 induced a twofold higher pressor response than that caused by intra-arterial injection of ET-1 and provoked a barostatic gain that was reduced by 2.5- to 3-fold compared with that calculated after intra-arterial administration of the peptide. The ET receptor antagonist bosentan significantly (P < 0.05) attenuated these responses regardless of the route of administration. Finally, intra-arterial injection of ET-1 did not significantly modify plasma cortisol level. The present data demonstrate that intracerebroventricular and intra-arterial administration of very low doses of ET-1 produces hypertension in conscious trout. The lack of effect of ET-3 indicates that the hemodynamic actions of ET-1 are mediated both centrally and peripherally through ETA receptors.

[Influence of glycemic control on peripheral nerve conduction in insulin-dependent diabetic subjects (author's transl)]. / Influence du contrôle glycémique sur la conduction nerveuse périphérique des diabétiques insulino-dépendants.

In order to better evaluate the influence of glycemic control on diabetic neuropathy, 73 diabetic patients were considered: 42 males and 31 females who had been treated with insulin during 9 years. Twenty-one subjects were examined during 2-12 months. Motor nerve conduction velocity (MCV) was measured on the external sciatic popliteus (ESP). The H reflex parameters from soleus were: latency time for H response (HL), the ratio between the maximum amplitude of the H reflex response and the M motor response: (formula: see text) was determined by a chromatographic method. The reduction of MCV, the rise in HL and the decrease of E in diabetics are more pronounced according to the duration of the disease and are significantly correlated with the rate of HbA1c (respectively MCV: r = -0.39, P less than 0.001; HL: r = 0.42, P less than 0.001; E: r = -0.37, P less than 0.01). There is a slight correlation between HbA1c level and the duration of diabetes. For the 21 diabetics observed during many months there is a very significant correlation between the slope of the evolution curves of HbA2c, MCV and HL.